| scholarly article | Q13442814 |
| P2093 | author name string | Elizabeth Ablah | |
| Dennis F Moore | |||
| Joseph A Moore | |||
| Philip Twumasi-Ankrah | |||
| Matthew B Moore | |||
| Dory Abou Jaoude | |||
| P2860 | cites work | MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 |
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. | Q30447832 | ||
| Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic Acid-guided surgery | Q30628099 | ||
| Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials | Q30686073 | ||
| Controversies in the adjuvant therapy of high-grade gliomas | Q33394265 | ||
| Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications | Q33854066 | ||
| Deltex-1 activates mitotic signaling and proliferation and increases the clonogenic and invasive potential of U373 and LN18 glioblastoma cells and correlates with patient survival | Q34603835 | ||
| High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34620657 | ||
| Long-term survival with glioblastoma multiforme | Q34676734 | ||
| A case of more than 20 years survival with glioblastoma, and development of cavernous angioma as a delayed complication of radiotherapy | Q38081221 | ||
| Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. | Q41642828 | ||
| Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. | Q42554303 | ||
| Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution | Q43153277 | ||
| Genetic pathways to glioblastoma: a population-based study | Q44673208 | ||
| Overexpression of SLC7A7 predicts poor progression-free and overall survival in patients with glioblastoma | Q45338889 | ||
| Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis. | Q45798961 | ||
| Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? | Q46079736 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. | Q46771343 | ||
| The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis | Q46915446 | ||
| Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. | Q48260300 | ||
| P433 | issue | 3 | |
| P921 | main subject | glioblastoma | Q282142 |
| P304 | page(s) | 65-69 | |
| P577 | publication date | 2019-08-21 | |
| P1476 | title | Glioblastoma and Increased Survival with Longer Chemotherapy Duration | |
| P478 | volume | 12 |
| Q89534156 | KIF3C is associated with favorable prognosis in glioma patients and may be regulated by PI3K/AKT/mTOR pathway | cites work | P2860 |
Search more.